In October 2007, the FDA introduced the labeling for all PDE5 inhibitors, such as tadalafil, requires a far more distinguished warning on the prospective risk of sudden hearing loss as the results of post-marketing and advertising studies of short-term deafness related to utilization of PDE5 inhibitors.[19]Seldom, more serious Negative effects or p